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Abstract
Background: With improvements in patient survival after a liver transplantation (LT), long-term seque-
lae such as metabolic syndrome (MS) have become increasingly common. This study aims to charac-
terize the prevalence, associations and long-term outcomes of post-LTMS and its components in an
Asian population.
Methods: A retrospective review of all adult patients who underwent LT at the National University
Health System Singapore between December 1996 and May 2012 was performed. MS was defined
using the Adult Treatment Panel (ATP) III criteria modified for an Asian population.
Results: The median age of this cohort of 90 patients was 50.0 (16.0–67.0) years, with a median fol-
low-up duration of 60.0 (7.0–192.0) months. The prevalence of post-LTMS was 35.6%, diabetes mell-
itus (DM) 51.1%, hypertension 60.0%, obesity 26.7% and dyslipidaemia 46.7%. On univariate analysis,
factors significantly associated with post-LT MS include female gender (P = 0.066), pre-LT respiratory
comorbidities (P = 0.038), pre-LT obesity (P = 0.014), pre-LTDM (P < 0.001), pre-LT hypertension
(P = 0.039), pre-LTMS (P < 0.001), prednisolone use ≥24 months (P = 0.005) and mycophenolate
mofetil use ≥24 months (P = 0.035). On multivariate analysis, independent associations of post-LT MS
were pre-LTDM (P = 0.011) and pre-LTMS (P = 0.024). There was no difference in long-term survival of
patients with and without post-LTMS (P = 0.425).
Conclusion: In conclusion, pre-LT components of the MS and the use of certain immunosuppres-
sants are related to developing post-LTMS.
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Introduction
Liver transplantation (LT) has seen vast improvements in sur-
gical techniques and immunosuppression over the past four
decades since the first successful human liver transplant per-
formed in 1967.1 LT is now considered a definitive treatment
for patients with end-stage liver disease and selected cases of
hepatocellular carcinoma.2–4 With LT achieving 5-year survival
rates in excess of 70% with modern management,3–5 long-term
sequelae of liver transplantation and lifelong immunosuppres-
sion have assumed greater clinical importance.
Post-LT metabolic syndrome (MS) has emerged as an
increasingly prevalent condition amongst post-LT patients.5–7
With the established association between MS and cardiovascu-
lar disease, it is not surprising to see an increasing proportion
of mortality and graft loss post-LT related to cardiovascular
disease.5
Many studies have looked at post-LT MS in Western popu-
lations8–12 but the applicability of such findings to an Asian
population remains unclear. There are differences between
body mass index (BMI), the percentage of body fat and health
risks when comparing European and Asian populations,
according to the World Health Organization (WHO) expert
consultation.13 As such, this study aims to characterize the
prevalence, predictive factors and long-term outcomes of post-
LT MS and its components in an Asian population, trans-
planted at an Asian centre.
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Methods
A retrospective chart review of all adult patients who under-
went LT and are on long-term follow-up at the National Uni-
versity Health System, Singapore from December 1996 to May
2012 was conducted. Patients with < 6 months of follow-up
duration at the time of the study were excluded. There was a
total of 90 patients included in the study.
The metabolic syndrome was defined using the National
Cholesterol Education Program (NCEP) Adult Treatment
Panel (ATP) III criteria,14 with a modification to the abdomi-
nal obesity criteria (Table 1). As proposed by a consensus
statement from the International Diabetes Federation, a body
mass index (BMI) of 30 kg/m2 in European populations can
be used as a surrogate indication of a waist circumference
exceeding the threshold required to fulfill the abdominal obes-
ity criteria.15 In order to better tailor the diagnostic criteria for
the MS to our study population, we used the corresponding
Asian BMI cut-off of 27.5 kg/m2 instead, in accordance with a
2004 WHO expert consultation.13
In addition, components of MS, namely diabetes mellitus
(DM), hypertension, dyslipidemia and obesity, were studied
individually. DM, hypertension and dyslipidemia were consid-
ered present if a medical diagnosis was recorded, or if the
patient was on pharmacological therapy for any of these condi-
tions. Details pertaining to the onset and progression of these
chronic conditions were also captured in the data collection
process. Obesity was defined by a BMI of 27.5 kg/m2 or
greater.13 Information related to morbidity and survival of the
patients with and without MS was documented, in particular,
those related to cardiovascular events that may be related to
MS.
Statistical analyses were performed using SPSS 19.0 (IBM,
Armonk, NY, USA). For univariate analyses, continuous vari-
ables were analysed using the Mann–Whitney U-test whereas
categorical variables were analysed using either the chi-square
or Fisher’s exact test. Subsequent multivariate analyses were
performed using logistic regression. Kaplan–Meier curves
were created for survival analysis in this study. A level of
significance of 5% was used.
Results
The median age in our study population was 50 (16–67) years
with a male preponderance (n = 69, 76.7%) and predominant
Chinese ethnicity (n = 69, 76.7%). The median duration of fol-
low-up was 60 (7–192) months. Hepatitis B cirrhosis (n = 45,
50.0%) comprised the majority of the underlying liver diseases
in our study population, followed by hepatitis C cirrhosis
(n = 11, 12.2%) and acute liver failure (n = 11, 12.2%). Addi-
tionally, nearly half the patients had hepatocellular carcinoma
(HCC) at the time of LT (n = 42, 46.7%). Of the 90 patients
we studied, 77 (85.6%) were deceased-donor liver transplanta-
tions.
The prevalence of post-LT MS in our study was 35.6% (n =
32), nearly double the percentage of patients with MS in the
pre-LT period (n = 17, 18.9%) (P = 0.001). There were 17
new patients who developed MS post-LT (Table 2). Of the 17
patients with pre-existing MS, two had a resolution of MS
post-LT. Both of them had hepatitis B cirrhosis with pre-exist-
ing hypertension. Incidentally, the resolution of MS was as a
result of a decrease in BMI in one patient and resolution of
the high-density lipoprotein (HDL) level in the other.
On univariate analysis, factors found to be significantly asso-
ciated with post-LT MS include the presence of pre-LT respira-
tory comorbidities, pre-LT components of the metabolic
syndrome such as DM, hypertension and obesity, pre-LT MS
itself and the use of immunosuppressants prednisolone or my-
cophenolate mofetil for 24 months or more (Table 3). Subse-
quent multivariate analysis revealed pre-LT DM and pre-LT
MS to each be independently associated with post-LT MS
(Table 3).
There were 46 (51.1%) post-LT DM, 54 (60.0%) post-LT
hypertension, 42 (46.7%) post-LT dyslipidemia and 24 (26.7%)
post-LT obesity cases, respectively. This reflects a 16.7%
increase in DM in the post-LT population (P = 0.001), and an
almost three-fold increase in post-LT hypertension (22.2% pre-
LT to 60.0% post-LT, P < 0.001). The percentage of patients
with pre-LT and post-LT dyslipidaemia were comparable
(P = 0.848). All in all, with the exception of obesity, the preva-
lence of MS and its components increased after LT (Table 2).
Table 1 Modified NCEP ATP III criteria for metabolic syndrome
Risk factors Defining level
(1) Abdominal obesity ≥27.5 kg/m2
(2) Triglyceride (TG) ≥150 mg/dl or pharmacologic treatment
(3) High-density
lipoprotein (HDL)
<40 mg/dl (male), <50 mg/dl (female)
or pharmacologic treatment
(4) Blood pressure (BP) ≥130/85 mmHg or pharmacologic
treatment
(5) Fasting glucose ≥110 mg/dl or pharmacologic treatment
The presence of ≥ 3 risk factors is required to diagnose metabolic syn-
drome.
Table 2 The prevalence of metabolic syndrome and its components
pre- and post-liver transplantation (LT)
Metabolic syndrome
component
Pre-LT (%) Post-LT (%) P-value*
Diabetes mellitus 31 (34.4) 46 (51.1) 0.001
Hypertension 20 (22.2) 54 (60.0) <0.001
Dyslipidemia 40 (44.4) 42 (46.7) 0.878
Obesity 28 (31.1) 24 (26.7) 0.481
Metabolic syndrome 17 (18.9) 32 (35.6) 0.001
*Statistical significance of P < 0.05.
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Univariate and subsequent multivariate analyses were also
performed for post-LT components of the MS. Post-LT
DM, hypertension and obesity were independently associated
with pre-LT DM, hypertension and obesity, respectively
(Tables 4–7).
Examining the long-term outcomes after liver transplanta-
tion, the prevalence of post-LT cardiovascular events was 4.4%
(n = 4), which was not found to be significantly associated
with post-LT MS (Table 3) and its components (Tables 4–7).
Using Kaplan–Meier analysis, we found that the overall sur-
vival of patients with post-LT (mean survival of
163  12 months) was comparable with those without post-
LT MS (mean survival of 148  10 months) (P = 0.425)
(Fig. 1). This observation was similar to all the components of
MS (Fig. 2). The median follow-up duration of the present
study was 60 (7–192) months.
Discussion
Alongside various Asian countries such as Japan, South Korea,
Taiwan and Hong Kong, LT has become an increasingly com-
mon surgical procedure with excellent long-term outcomes in
Singapore, with a 5-year survival post-LT well above 70%.4,16,17
The success of LT today attributable to advancements in
Table 3 Factors associated with post-liver transplantation (LT) metabolic syndrome (MS)
Factor Post-LT MS (%) Univariate analysis Multivariate analysis
Yes (n = 32) No (n = 58) OR (95% CI) P-value OR (95% CI) P-value
Median age (range) 53 (39–65) 49 (16–67) – 0.255 – –
Male 21 (65.6) 48 (82.8) 0.40 (0.15–1.08) 0.066 – –
Chinese 23 (71.9) 46 (79.3) 0.67 (0.25–1.81) 0.425 – –
Smoking 8 (27.6) 16 (32.7) 0.79 (0.29–2.16) 0.639 – –
Alcohol 10 (33.3) 16 (32.7) 1.03 (0.39–2.71) 0.950 – –
Median follow-up duration (months) (range) 79 (22–192) 58 (7–187) – 0.186 – –
Cardiac comorbidities 2 (6.3) 5 (8.6) 0.71 (0.13–3.87) NS* – –
Respiratory comorbidities 7 (21.9) 4 (6.9) 3.78 (1.01–14.1) 0.049* 2.05 (0.33–12.66) 0.440
Renal comorbidities 4 (12.5) 3 (5.2) 2.62 (0.55–12.52) 0.241* – –
Acute liver failure 1 (3.1) 10 (17.2) 0.16 (0.02–1.27) 0.089* – –
Hepatitis B cirrhosis 15 (46.9) 30 (51.7) 0.82 (0.35–1.96) 0.660 – –
Hepatitis C cirrhosis 6 (18.8) 5 (8.6) 2.45 (0.68–8.77) 0.189* – –
Alcoholic cirrhosis 4 (12.5) 4 (6.9) 1.93 (0.45–8.30) 0.448* – –
Autoimmune liver diseases 5 (15.6) 5 (8.6) 1.96 (0.52–7.37) 0.311 – –
Hepatocellular carcinoma 14 (43.8) 28 (48.3) 0.83 (0.35–1.99) 0.680 – –
Pre-LT DM 19 (59.4) 12 (20.7) 5.60 (2.17–14.48) <0.001 5.37 (1.48–19.47) 0.011
Pre-LT hypertension 11 (34.4) 9 (15.5) 2.85 (1.03–7.90) 0.039 1.20 (0.21–6.82) 0.840
Pre-LT dyslipidemia 18 (56.3) 22 (37.9) 2.10 (0.88–5.06) 0.094 – –
Pre-LT obesity 15 (46.9) 13 (22.4) 2.28 (1.15–3.32) 0.014 1.87 (0.45–7.80) 0.388
Pre-LT MS 15 (46.9) 2 (3.4) 24.71 (5.13–119.00) <0.001* 10.84 (1.37–86.05) 0.024
Prednisolone use ≥24 months 8 (25.8) 3 (5.2) 6.38 (1.55–26.21) 0.014* 3.43 (0.42–28.14) 0.251
Cyclosporine use ≥24 months 4 (12.5) 7 (12.1) 1.04 (0.28–3.87) NS* – –
Tacrolimus use ≥24 months 24 (75.0) 32 (55.2) 2.44 (0.94–6.32) 0.063 – –
Sirolimus use ≥24 months 2 (6.3) 5 (8.6) 0.71 (0.13–3.87) NS* – –
Mycophenolate mofetil use ≥24 months 14 (43.8) 13 (22.4) 2.69 (1.06–6.84) 0.034 1.27 (0.35–4.62) 0.714
Azathioprine use ≥24 months 5 (15.6) 8 (13.8) 1.16 (0.35–3.89) 0.813 – –
Acute graft rejection 16 (50.0) 20 (34.5) 1.90 (0.79–4.58) 0.150 – –
Chronic rejection 1 (3.1) 1 (1.7) 1.84 (0.11–30.42) NS* – –
Post-LT hepatitis B or C 13 (40.6) 17 (29.3) 1.65 (0.67–4.08) 0.276 – –
Post-LT cardiovascular event 1 (3.1) 3 (5.2) 0.59 (0.06–5.93) 0.150* – –
Statistical significance of P < 0.05 used.
*Fisher’s exact test.
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surgical techniques and post-LT immunosuppression has set
the stage for long-term sequelae such as post-LT metabolic
syndrome in these patients. The prevalence of post-LT MS in
our study population stands at 35.6%, a near two-fold increase
from the pre-LT prevalence of 18.9%, a finding consistent with
several previous studies.8–11 A similar trend of increased preva-
lence post-LT is also seen for the components of MS compo-
nents in our study, particularly DM and hypertension.
Aside from the implications for post-LT patient manage-
ment drawn from what we have learnt, our study also demon-
strates the implications of diagnostic criteria used for
identifying patients with MS. As delineated earlier, we chose
to modify the original NCEP ATP III criteria for the diag-
nosis of MS based on BMI cut-offs appropriate for an Asian
population.13,14 Employing this, our reported prevalence of
post-LT obesity and MS are 26.7% and 35.6%, respectively,
which would otherwise have been placed at 5.6% and
30.0%, respectively, using a conventional BMI cut-off of
30.0 kg/m2. Existing literature has established a similar risk
profile for cardiovascular morbidity and mortality amongst
Asian individuals at lower BMI ranges compared with their
Western counterparts.13 As such, using conventional BMI
cut-offs with its attendant under-reporting of obesity and
MS prevalence would accord a false sense of security
Table 4 Factors associated with post-liver transplantation (LT) diabetes mellitus (DM)
Factor Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Median age (range) – 0.666 – –
Male 0.94 (0.35–2.49) 0.894 – –
Chinese 1.20 (0.45–3.19) 0.715 – –
Smoking 1.27 (0.49–3.34) 0.624 – –
Alcohol 1.21 (0.47–3.10) 0.689 – –
Median follow-up duration (months) (range) – 0.161 – –
Cardiac comorbidities 1.30 (0.27–6.18) NS* – –
Respiratory comorbidities 1.80 (0.49–6.62) 0.523* – –
Renal comorbidities 2.56 (0.47–13.95) 0.435* – –
Acute liver failure 1.17 (0.33–4.15) 0.808 – –
Hepatitis B cirrhosis 1.00 (0.44–2.29) NS – –
Hepatitis C cirrhosis 1.80 (0.49–6.62) 0.523* – –
Alcoholic cirrhosis 0.95 (0.22–4.07) NS* – –
Autoimmune liver diseases 0.60 (0.16–2.30) 0.518* – –
Hepatocellular carcinoma 1.10 (0.48–2.52) 0.822 – –
Pre-LT DM 21.26 (5.72–79.05) <0.001* 18.76 (4.96–70.91) <0.001
Pre-LT hypertension 0.73 (0.27–1.98) 0.535 – –
Pre-LT dyslipidemia 1.91 (0.82–4.44) 0.131 – –
Pre-LT obesity 1.42 (0.58–3.50) 0.442 – –
Pre-LT MS 3.94 (1.17–13.23) 0.030* 1.99 (0.46–8.59) 0.358
Prednisolone use ≥24 months 1.20 (0.34–4.26) 0.778 – –
Cyclosporine use ≥24 months 1.80 (0.49–6.62) 0.523* – –
Tacrolimus use ≥24 months 1.91 (0.80–4.52) 0.142 – –
Sirolimus use ≥24 months 0.36 (0.07–1.93) 0.261* – –
Mycophenolate mofetil use ≥24 months 2.50 (0.98–6.41) 0.053 – –
Azathioprine use ≥24 months 2.43 (0.69–8.57) 0.231* – –
Acute graft rejection 1.96 (0.83–4.64) 0.121 – –
Chronic rejection 0.96 (0.06–15.76) NS* – –
Post-LT hepatitis B or C 1.40 (0.58–3.38) 0.456 – –
Post-LT cardiovascular event 3.00 (0.30–29.99) 0.617* – –
*Fisher’s exact test.
Statistical significance of P < 0.05 used.
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amongst Asian populations with regards to cardiovascular
risk, while potentially delaying medical interventions for
Asian patients with MS and its components.
Various associations of post-LT MS have been reported in
the literature, ranging from the use of certain immunosup-
pressive agents to lifestyle factors such as diet and physical
activity.8–12 A recurring association of post-LT MS and some
of its components in our study is the presence of pre-existing
MS or its components. This seemingly unsurprising finding
fundamentally highlights that patients with MS and/or its
components before LT constitute a high-risk group to which
interventions ought to be targeted. Interestingly, two of our
patients with pre-existing MS experienced resolution of MS
after LT. These two patients in our study had hepatitis B
cirrhosis and pre-existing hypertension prior to LT. After LT,
resolution of MS was attributable to a decrease in BMI in
one patient and resolution of a low serum HDL level in the
other. On a related note, recent reports of LT in obese
patients demonstrated the possibility of combining LT with
bariatric surgical procedures such as a sleeve gastrectomy in
order to achieve effective weight loss and resolution of MS
after LT. However, the timing, indications and type of bariat-
ric surgery to be employed in this patient group remains a
largely controversial area.18,19
Table 5 Factors associated with post-liver transplantation (LT) hypertension
Factor Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Median age (range) – 0.082 – –
Male 0.69 (0.25–1.92) 0.476 – –
Chinese 1.94 (0.72–5.20) 0.186 – –
Smoking 0.98 (0.36–2.65) 0.969 – –
Alcohol 1.15 (0.43–3.05) 0.787 – –
Median follow-up duration (months) (range) – 0.082 – –
Cardiac comorbidities 0.24 (0.04–1.30) 0.111* – –
Respiratory comorbidities 0.78 (0.22–2.76) 0.693 – –
Renal comorbidities 4.38 (0.50–37.99) 0.236* – –
Acute liver failure 0.33 (0.09–1.23) 0.108* – –
Hepatitis B cirrhosis 1.45 (0.62–3.38) 0.389 – –
Hepatitis C cirrhosis 1.19 (0.32–4.41) NS* – –
Alcoholic cirrhosis 2.13 (0.40–11.17) 0.468* – –
Autoimmune liver diseases 1.00 (0.26–3.83) NS* – –
Hepatocellular carcinoma 1.69 (0.72–3.99) 0.227 – –
Pre-LT DM 2.06 (0.81–5.22) 0.124 – –
Pre-LT hypertension 19.00 (2.41–149.78) <0.001* 10.31 (1.22–86.91) 0.032
Pre-LT dyslipidemia 0.83 (0.36–1.94) 0.665 – –
Pre-LT obesity 1.30 (0.52–3.27) 0.577 – –
Pre-LT MS 14.74 (1.86–117.00) 0.002 7.93 (0.92–68.40) 0.060
Prednisolone use ≥24 months 8.14 (0.99–66.70) 0.025* 3.39 (0.34–34.04) 0.299
Cyclosporine use ≥24 months 1.19 (0.32–4.41) NS* – –
Tacrolimus use ≥24 months 2.38 (0.99–5.71) 0.051 – –
Sirolimus use ≥24 months 0.47 (0.10–2.24) 0.431* – –
Mycophenolate mofetil use ≥24 months 0.96 (0.38–2.40) 0.925 – –
Azathioprine use ≥24 months 4.35 (0.90–20.95) 0.067* – –
Acute graft rejection 1.96 (0.81–4.76) 0.135 – –
Chronic rejection 0.66 (0.04–10.91) NS* – –
Post-LT hepatitis B or C 1.53 (0.61–3.82) 0.361 – –
Post-LT cardiovascular event 2.06 (0.21–20.61) 0.647* – –
Statistical significance of P < 0.05 used.
*Fisher’s exact test.
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Aside from the presence of MS or its components pre-LT, we
found a trend towards a higher prevalence of post-LT MS,
hypertension and obesity with the long-term use of predniso-
lone and/or mycophenolate mofetil. The mechanistic role of
corticosteroids in the pathogenesis of MS and its components
through a variety of physiological mechanisms seems to be
more established. Corticosteroids promote insulin resistance
through a down-regulation of insulin production, up-regulation
of hepatic gluconeogenesis and decrease in glucose utilization
in peripheral tissues.20,21 Additionally, the mineralocorticoid
activity that corticosteroids partially exhibit contributes to the
development of hypertension through renal retention of sodium
and water and direct activation of vascular smooth muscle.19,21
Although less extensively studied, mycophenolate mofetil has
similarly been reported to be associated with increased odds of
post-LT cardiovascular events.22
Additionally, we found a possible association between post-
LT MS and its components with hepatitis C infection, specifi-
cally a trend towards a higher prevalence of post-LT MS with
pre-LT hepatitis C cirrhosis, as well as an independent associa-
tion between post-LT dyslipidemia and post-LT hepatitis B or
C infection. Hepatitis C cirrhosis has been implicated in the
development of post-LT MS in multiple studies,5–7,9,12 a rela-
tionship attributable to a multitude of pathophysiological
Table 6 Factors associated with post-liver transplantation (LT) dyslipidemia
Factor Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Median age (range) – 0.471 – –
Male 2.72 (0.95–7.87) 0.058 – –
Chinese 1.58 (0.58–4.29) 0.369 – –
Smoking 1.00 (0.38–2.62) NS – –
Alcohol 0.89 (0.35–2.28) 0.808 – –
Median follow-up duration (months) (range) – 0.091 – –
Cardiac comorbidities 0.43 (0.08–2.34) 0.442* – –
Respiratory comorbidities 1.43 (0.40–5.09) 0.576 – –
Renal comorbidities 3.11 (0.57–16.95) 0.245* – –
Acute liver failure 0.62 (0.17–2.27) 0.533* – –
Hepatitis B cirrhosis 1.00 (0.44–2.29) NS – –
Hepatitis C cirrhosis 2.20 (0.60–8.12) 0.335* – –
Alcoholic cirrhosis 1.16 (0.27–4.95) NS* – –
Autoimmune liver diseases 0.74 (0.19–2.81) 0.745* – –
Hepatocellular carcinoma 0.90 (0.39–2.06) 0.799 – –
Pre-LT DM 2.02 (0.84–4.88) 0.116 – –
Pre-LT hypertension 2.63 (0.93–7.39) 0.062 – –
Pre-LT dyslipidemia 1.27 (0.55–2.93) 0.571 – –
Pre-LT obesity 1.85 (0.75–4.55) 0.181 – –
Pre-LT MS 3.44 (1.10–10.79) 0.028 4.58 (1.37–15.32) 0.013
Prednisolone use ≥24 months 3.45 (0.85–14.00) 0.106* – –
Cyclosporine use ≥24 months 2.20 (0.60–8.12) 0.335* – –
Tacrolimus use ≥24 months 1.74 (0.73–4.13) 0.212 – –
Sirolimus use ≥24 months 0.85 (0.18–4.02) NS* – –
Mycophenolate mofetil use ≥24 months 1.67 (0.67–4.13) 0.268 – –
Azathioprine use ≥24 months 0.98 (0.30–3.17) 0.968 – –
Acute graft rejection 0.59 (0.25–1.39) 0.227 – –
Chronic rejection – 0.497* – –
Post-LT hepatitis B or C 3.46 (1.37–8.69) 0.007 4.25 (1.61–11.24) 0.004
Post-LT cardiovascular event 0.37 (0.04–3.66) 0.620* – –
Statistical significance of P < 0.05 used.
*Fisher’s exact test.
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mechanisms including direct induction of hepatocyte insulin
resistance and increased systemic levels of tumour necrosis
factor-a and other inflammatory cytokines altering the lipid
oxidation pathways.11,23 In addition, a meta-analysis demon-
strating a significantly higher rate of post-LT DM in hepatitis
C virus-positive recipients compared to hepatitis C virus-
negative recipients (54% versus 38%)24 further suggests that
hepatitis C infection exerts an influence on the development
of metabolic syndrome components even if it is acquired
after LT.
In examining if the presence of MS impacts patients post-LT
in the long-run, we looked specifically at the outcome mea-
sures of cardiovascular events and long-term survival. We did
not find any significant difference when comparing patients
with and without post-LT MS, in contrast to findings reported
by several other studies.6,9,10,25 Possible factors accounting for
this difference include potential differences in the stringency of
patient selection for LT between different institutions and a
younger median age of our study population compared to
these other studies. All patients underwent rigorous cardiac
evaluation when referred to our institution for liver transplan-
tation. Consequently, patients with significant ischaemic heart
disease or other cardiac conditions were not transplanted. We
are in the process of reviewing our results on cardiac evalua-
tion in pre-LT patients to better select candidates that will ben-
efit from LT while weighing it up against their cardiac risk.
Table 7 Factors associated with post-liver transplantation (LT) obesity
Factor Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Median age (range) – 0.226 – –
Male 0.28 (0.10–0.79) 0.013 0.28 (0.07–1.17) 0.081
Chinese 0.37 (0.13–1.04) 0.055 – –
Smoking 0.48 (0.14–1.61) 0.273* – –
Alcohol 1.03 (0.36–2.96) 0.962 – –
Median follow-up duration (months) (range) – 0.888 – –
Cardiac comorbidities 1.11 (0.20–6.14) NS* – –
Respiratory comorbidities 2.63 (0.72–9.60) 0.133 – –
Renal comorbidities 1.11 (0.20–6.14) NS* – –
Acute liver failure 1.04 (0.25–4.28) NS* – –
Hepatitis B cirrhosis 0.63 (0.25–1.63) 0.340 – –
Hepatitis C cirrhosis 1.04 (0.25–4.28) NS* – –
Alcoholic cirrhosis 1.74 (0.38–7.93) 0.435* – –
Autoimmune liver diseases 2.00 (0.51–7.81) 0.447* – –
Hepatocellular carcinoma 0.47 (0.18–1.25) 0.126 – –
Pre-LT DM 1.95 (0.75–5.08) 0.170 – –
Pre-LT hypertension 3.00 (1.05–8.57) 0.036 1.05 (0.15–7.27) 0.963
Pre-LT dyslipidemia 4.54 (1.65–12.53) 0.002 3.69 (0.88–15.58) 0.075
Pre-LT obesity 12.14 (4.07–36.21) <0.001 8.38 (2.11–33.33) 0.003
Pre-LT MS 24.71 (5.13–119.00) <0.001* 3.48 (0.51–23.52) 0.202
Prednisolone use ≥24 months 4.00 (1.09–14.65) 0.028 3.17 (0.45–22.38) 0.247
Cyclosporine use ≥24 months 1.69 (0.45–6.37) 0.475* – –
Tacrolimus use ≥24 months 1.30 (0.49–3.47) 0.600 – –
Sirolimus use ≥24 months 0.44 (0.05–3.81) 0.670* – –
Mycophenolate mofetil use ≥24 months 2.64 (0.99–7.05) 0.048 1.93 (0.47–7.94) 0.365
Azathioprine use ≥24 months 1.27 (0.35–4.57) 0.740* – –
Acute graft rejection 2.21 (0.86–5.71) 0.098 – –
Chronic rejection – NS* – –
Post-LT hepatitis B or C 0.58 (0.20–1.67) 0.312 – –
Post-LT cardiovascular event – 0.570* – –
Statistical significance of P < 0.05 used.
*Fisher’s exact test.
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Furthermore, our median duration of follow-up of 60 months
may be relatively short when looking at long-term outcomes
pertaining to survival and cardiovascular outcomes. Lastly, the
small number of patients in our study could also contribute to
this apparent discrepancy. Nonetheless, in extrapolation from
the effects on long-term cardiovascular events and survival
found in both the non-transplant and liver transplant popula-
tions in existing literature, we believe the presence of post-LT
MS and its components is a clinically significant issue. This is
especially so when the long-term outlook and survival of
patients after LT are improving, which means that more of
such patients will live to see the effects of the MS after LT.
With the recognition of MS and its components becoming
an important issue in the holistic care of post-LT patients,
more emphasis could potentially be placed on various
aspects of their management and follow-up. First, post-LT
patients could benefit from close and regular monitoring of
clinical parameters pertaining to MS such as height, weight,
waist circumference, fasting blood glucose, blood pressure
and fasting lipids. Should sustained derangements in these
parameters be detected, subsequent referral to appropriate
avenues of care and treatment should be initiated.15 For
Figure 1 Long-term survival of patients with and without post-liver
transplantation (LT) metabolic syndrome (MS)
Figure 2 Long-term survival of patients with and without post-liver transplantation (LT) metabolic syndrome (MS) components
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patients with pre-existing MS and its components prior to
LT, multidisciplinary teams could formulate multi-faceted
care plans comprising lifestyle modifications and optimiza-
tion of pharmacological therapy tailored to specific consider-
ations pertaining to post-LT patients. Furthermore,
modifications to the immunosuppression regime to minimize
the use of drugs associated with MS and its components
could be initiated in the long-term management of these
patients.6,26 Such interventions, where feasible, could also be
extended to patients without pre-existing MS for the pur-
pose of primary prevention, especially for those with charac-
teristics established as having independent associations for
developing MS post-LT.
A major limitation of our study is its retrospective nature,
which limits the ability to establish causal relationships
between post-LT metabolic outcomes and related factors. How-
ever, for factors with a defined temporal relationship prior to
the development of post-LT MS and its components, such as
pre-existing comorbidities and pre-LT MS components, a cau-
sal relationship can still be reliably inferred. Also, the pre-LT
BMI could have been overestimated for a proportion of
patients owing to the presence of ascites prior to LT. In addi-
tion to the duration of immunosuppressive agents used, a
dose-dependent association with post-LT metabolic outcomes
could have been explored as well if the data were available.
Conclusion
MS and its components are prevalent after LT. Factors inde-
pendently associated with increased odds of post-LT MS and
its components include pre-LT MS components and post-LT
hepatitis B or C (for post-LT dyslipidaemia). Long-term car-
diovascular outcomes and survival after LT are comparable
between patients with and without post-LT MS and its compo-
nents in our study. Further studies should delve into longer-
term follow-up of patients to better determine the effect of
post-LT MS and its components on cardiovascular events and
survival, as well as the potential interventions to minimize the
risk of developing them post-LT.
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